EvoBiotech is a biotechnology start-up working on extracellular vesicles building on more than 20 years of expertise in the field.
Our proprietary technology exploits the natural ability of EV to deliver bioactive molecules to target cells and our focus is to use plant-derived extracellular vesicles as an innovative solution to improve the efficacy of therapies and provide new delivery systems.
11th July 2023
EvoBiotech published its last results on the use of extracellular vesicles derived from plants as a drug delivery system in the special issue “Extracellular Vesicles and Nucleic Acids in Health and Disease” of Cells Journal. This work demonstrates the use of edible plant-derived extracellular vesicles to vehicle mRNA-based vaccines for SARS-CoV-2 using an easy-to-use formulation […]
2nd June 2023
EU Startup.news is a popular website covering news about the European startup landscape and pointing-out the most promising startups for investment opportunities. We are pleased to share that EvoBiotech has been cited as one of the 15 innovative Italian Startups that are revolutionizing biotechnology in Italy. According to EU Startup.news, EvoBiotech is a cutting-edge biotech […]
24th May 2023
EvoBiotech participated to the Annual Meeting of International Society for Extracellular Vesicles (International ISEV 2023) in Seattle to present its last results on the innovative use of plant extracellular vesicles as a delivery platform for mRNA-based vaccines.